GlaxoSmithKline’s application for approval of mepolizumab as an add-on therapy to reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD) requires more clinical data, the U.S. Food and Drug Administration (FDA) said in a complete response letter. GSK sought approval for mepolizumab as an add-on to inhaled corticosteroid-based maintenance treatments used…
News
Two Phase 2 Trials Demonstrate RPL554 Has Potential to Enhance Bronchodilators’ Efficacy in COPD
The addition of Verona Pharma’s investigational agent RPL554 to standard short- and long-acting bronchodilators offers greater clinical benefits to patients with chronic obstructive pulmonary disease (COPD). Results of two Phase 2 clinical trials (NCT02542254 and NCT03028142) demonstrated that the RPL554 add-on could enhance the bronchodilation action…
Testosterone replacement therapy can help slow the progression of chronic obstructive pulmonary disease (COPD) in men, a new study shows. Men with COPD tend to experience shortness of breath, leading physicians to prescribe them long-term steroid-based medications. While these medications help treat pulmonary symptoms, they are also associated with…
Electronic cigarettes help reduce exacerbations and improve exercise capacity in patients with chronic obstructive pulmonary disease (COPD) who saw their condition get worse by smoking conventional cigarettes, a new study reports. The study, “Health effects in COPD smokers who switch to electronic cigarettes: a retrospective-prospective 3-year follow-up” was…
Digital health company Adherium recently launched the Hailie solution in the U.S., a technology designed to help patients with asthma and chronic obstructive pulmonary disease (COPD) track their medication usage and better manage their condition. This follows a 510(k) over-the-counter clearance from the U.S. Food and Drug Administration that allows…
AstraZeneca’s Bevespi Aerosphere (glycopyrrolate/formoterol fumarate) has been shown to have similar therapeutic activity in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) as GlaxoSmithKline’s approved therapy Anoro Elipta (umeclidinium/vilanterol). Bevespi Aerosphere combines a fixed dose of two bronchodilators — glycopyrrolate, a…
A specific gene variation associated with chronic obstructive pulmonary disease (COPD) is also linked with autoimmune disorders, according to a large genetic study, suggesting a role for autoimmune responses in the development of COPD. The study, “A Phenome-Wide Association Study Uncovers a Role for Autoimmunity in the…
High frequency chest wall oscillation (HFCWO) vests, a type of airway clearance therapy used in several lung disorders, including chronic obstructive pulmonary disease (COPD), were not found to improve measures of lung function in healthy individuals in a recent study. The study, designed to assess the short-term…
Hospitalized patients with chronic obstructive pulmonary disease (COPD) who also suffer from atrial fibrillation (AFib), a condition where the heart beats faster, have a greater risk of developing liver disease and respiratory failure compared to those not affected by AFib, according to researchers. Their study, “…
Verona Pharma has started a Phase 2 clinical trial to evaluate the potential of its nebulized RPL554 as an add-on treatment to the approved Stiolto Respimat (tiotropium bromide/olodaterol) for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD). A total of 75 patients are expected to…
Recent Posts
- Oxygen tubing brings me breath, clarity, and independence
- Erasing the stigma of supplemental oxygen so that we can breathe again
- New nebulized combo therapy rapidly boosts lung function in COPD
- I’m going forward, but I don’t need to break the sound barrier to be heard
- A low‑grade fever saps my ambition and steals the day away from me